GlaxoSmithKline, Novartis and Astellas are among the investors to have celebrated an exit after cancer therapy developer Bicycle secured $60.7m in its initial public offering.

Bicycle Therapeutics, a UK-based developer of treatments for diseases with a high unmet need backed by corporates Novartis, GlaxoSmithKline and Astellas, floated on the Nasdaq Global Market yesterday in a $60.7m initial public offering.

The company issued approximately 4.3 million American Depositary Shares, equivalent to the same number of ordinary shares, priced at $14.00 each, at the bottom of the $14 to $16 range set for the offering, valuing it at $248m. Its shares dropped to $12 by the…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn